Photo from Mohammad Jad Moussa/X
Jun 15, 2024, 05:45
Mohammad Jad Moussa: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation
Mohammad Jad Moussa, Postdoc Fellow of GU Oncology at MD Anderson Cancer Center, shared a post on X:
“NOW IN PRESS: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
- GU ASCO GU24: Original multi-institutional series on off-label use of lurbi in SCBC-enriched GU cohorts Omar Alhalabi, Parminder Singh, Alan Bryce.
- ASCO24: Phase II LASER study announcement (lurbi +/- avelumab) Saad Atiq, Andrea Apolo
- Now: Our structured report Current Oncology with a hypothesis-testing paradigm, awaiting objective response.”
Read further.
Source: Mohammad Jad Moussa/X
Alan Bryce
Andrea Apolo
ASCO GU24
cancer
Current Oncology
durable objective response
hypothesis-testing paradigm
lurbi +/- avelumab
Lurbinectedin
MD Anderson Cancer Center
Mohammad Jad Moussa
molecular-directed strategy
multi-institutional series
objective response
off-label use
Omar Alhalabi
OncoDaily
Oncology
Parminder Singh
Phase II LASER study
Postdoc Fellow of GU Oncology
Saad Atiq
SCBC-enriched GU cohorts
small cell bladder cancer
TP53 mutation
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14